Aethlon Medical logo

Aethlon MedicalNASDAQ: AEMD

Profile

Sector:

Healthcare

Country:

United States

IPO:

04 March 1999

Next earnings report:

14 February 2025

Last dividends:

N/A

Next dividends:

N/A
$5.47 M
-86%vs. 3y high
13%vs. sector
-vs. 3y high
-vs. sector
-58%vs. 3y high
37%vs. sector
-vs. 3y high
-vs. sector

Price

regular market | 27 min ago
$0.39+$0.01(+2.41%)

Dividend

No data over the past 3 years

Analysts recommendations

Institutional Ownership

AEMD Latest News

Aethlon Medical, Inc. (AEMD) Q2 2025 Earnings Call Transcript
seekingalpha.com13 November 2024 Sentiment: NEUTRAL

Aethlon Medical, Inc. (NASDAQ:AEMD ) Q2 2025Earnings Conference Call November 13, 2024 4:30 PM ET Company Participants Michael Miller - Investor Relations, Rx Communications James Frakes - Interim Chief Executive Officer & Chief Financial Officer Steven LaRosa - Chief Medical Officer Conference Call Participants Marla Marin - Zacks Jeremy Pearlman - Maxim Group Operator Good day, and welcome to the Aethlon Medical Fiscal Second Quarter 2025 Earnings and Corporate Update. [Operator Instructions] Please note this event is being recorded.

Aethlon Medical Announces Financial Results for the Fiscal Second Quarter Ended September 30, 2024 and Provides Corporate Update
prnewswire.com13 November 2024 Sentiment: POSITIVE

Achieves Key Milestone with Enrollment of First Two Patients in the Safety, Feasibility, and Dose Finding Study of Aethlon's Hemopurifier® in Patients with Solid Tumors Not Responding to Anti-PD-1 Antibodies Two Australian Sites Open For Patient Enrollment in Hemopurifier® Cancer Trial Conference Call to be Held Today at 4:30 p.m. ET SAN DIEGO , Nov. 13, 2024 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases, today reported financial results for its fiscal second quarter ended September 30, 2024 and provided an update on recent developments.

Innovative Medical Technology Advances with First Patient Enrollments
newsfilecorp.com12 November 2024 Sentiment: POSITIVE

Vancouver, Kelowna, and Delta, British Columbia--(Newsfile Corp. - November 12, 2024) - Investorideas.com, a go-to investing platform, releases an industry snapshot looking at the future of medical technology as first patients are enrolled in potential breakthrough trials, featuring Aethlon Medical, Inc. (NASDAQ: AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases. Read the full article on Investorideas.com https://www.investorideas.com/News/2024/biotech/11120AEMD-First-Patient-Enrollments.asp According to Statista.com, "The Medical Technology market, which encompasses various markets, including Medical Devices, is anticipated to witness significant revenue growth in the coming years.

Aethlon Medical to Release Fiscal Second Quarter Financial Results and Host Conference Call on November 13, 2024
prnewswire.com06 November 2024 Sentiment: POSITIVE

SAN DIEGO , Nov. 6, 2024 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life threatening infectious diseases, today announced that it will issue financial results for its fiscal second quarter ended September 30, 2024, at 4:15 p.m. ET on Wednesday, November 13, 2024.

Aethlon Medical to Participate in the 2024 Maxim Healthcare Virtual Summit
prnewswire.com08 October 2024 Sentiment: POSITIVE

SAN DIEGO , Oct. 8, 2024 /PRNewswire/ -- Aethlon Medical, Inc.  (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases, today announced that James Frakes, Chief Executive Officer and Chief Financial Officer, will participate in a fireside chat at the 2024 Maxim Healthcare Virtual Summit, hosted by Anthony Vendetti, executive managing director and head of research at Maxim Group, on Tuesday, October 15, 2024 at 4:30 pm ET. To listen to the company presentation, sign up for the conference using this link.

Aethlon Receives Ethics Committee Approval for Hemopurifier® Cancer Trial in India
prnewswire.com19 September 2024 Sentiment: POSITIVE

Aethlon Medical Granted Full Ethics Approval from the Medanta Institutional Ethics Committee for a Safety, Feasibility, and Dose Finding Study of its Hemopurifier® in Cancer Patients with Solid Tumors Not Responding to Anti-PD-1 Antibodies SAN DIEGO , Sept. 19, 2024 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life threatening infectious diseases, today announced that, on September 9, 2024, the Medanta Institutional Ethics Committee (MIEC) granted full ethics approval for Aethlon's safety, feasibility and dose-finding clinical trial of the Hemopurifier® in cancer patients with solid tumors who have stable or progressive disease during anti-PD-1 monotherapy treatment, such as Keytruda® (pembrolizumab) or Opdivo® (nivolumab) (AEMD-2022-06 Hemopurifier Study).

Aethlon Medical to Present at Virtual Investor Conferences in September
prnewswire.com17 September 2024 Sentiment: POSITIVE

SAN DIEGO , Sept. 17, 2024 /PRNewswire/ -- Aethlon Medical, Inc.  (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases, today announced that management will present at the following virtual investor conferences in September: September 19-20: Life Sciences Investor Forum: James Frakes, Interim Chief Executive Officer and Chief Financial Officer and Steven LaRosa, MD, Chief Medical Officer, will present a company overview at this conference, hosted by virtualinvestorconferences.com, on Thursday, September 19, 2024 at 1:30 pm ET.

Innovation Driving Cancer's Solid Tumors Market
newsfilecorp.com17 September 2024 Sentiment: POSITIVE

Vancouver, Kelowna, and Delta, British Columbia--(Newsfile Corp. - September 17, 2024) - Investorideas.com, a go-to investing platform, releases the first of a two-part series looking at news and developments for the treatment of cancer and solid tumors featuring Aethlon Medical, Inc. (NASDAQ: AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening viral infections. Read the full article at Investorideas.com https://www.investorideas.com/News/2024/biotech/09170Solid-Tumors-Market.asp According to Biospace.com "The solid tumors market size reached a value of US$ 170.3 Billion in 2023.

Aethlon Medical Announces Activation of Royal Adelaide Hospital to Begin Patient Screening and Enrollment in Hemopurifier® Cancer Trial
prnewswire.com16 September 2024 Sentiment: POSITIVE

Aethlon's Trial is a Safety, Feasibility, and Dose Finding Study of the Hemopurifier® in Patients with Solid Tumors Not Responding to Anti-PD-1 Antibodies SAN DIEGO , Sept. 16, 2024 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases, today announced that the Cancer Clinical Trial Unit at Royal Adelaide Hospital was activated on September 10, 2024 to begin screening and enrolling patients in its safety, feasibility and dose-finding clinical trial of the Hemopurifier® in patients with solid tumors who have stable or progressive disease during anti-PD-1 monotherapy treatment, such as Keytruda® (pembrolizumab) or Opdivo® (nivolumab) (AEMD-2022-06 Hemopurifier Study).

Aethlon Medical Announces Publication of Preclinical Data Showing Ability of the Hemopurifier® to Remove Extracellular Vesicles and microRNAs from Renal Perfusates Following Controlled Oxygenated Rewarming of Discarded Donor Kidneys
prnewswire.com27 August 2024 Sentiment: POSITIVE

Results Support Future Study of the Hemopurifier® as Part of a Machine Perfusion Circuit to Further Assess its Association with Function of Retrieved Kidneys SAN DIEGO , Aug. 27, 2024 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases, today announced the publication in preprint of an in vitro study in bioRxiv on August 24, 2024, entitled, "The Hemopurifier® Removes Extracellular Vesicles and microRNAs From Renal Perfusates Following Controlled Oxygenated Rewarming of Discarded Donor Kidneys." Aethlon Medical's Hemopurifier® is a therapeutic blood filtration system designed to bind and remove harmful exosomes and life-threatening viruses from blood and other biological fluids, qualities which have potential applications in oncology and infectious diseases, as well as in the organ transplant setting.

  • 1(current)

What type of business is Aethlon Medical?

Aethlon Medical, Inc., a medical therapeutic company, focuses on developing products to treat cancer and life-threatening infectious diseases in the United States. It develops Hemopurifier, a clinical-stage immunotherapeutic device for cancer and life-threatening viral infections and use in organ transplantation. The company was founded in 1984 and is based in San Diego, California.

What sector is Aethlon Medical in?

Aethlon Medical is in the Healthcare sector

What industry is Aethlon Medical in?

Aethlon Medical is in the Medical Devices industry

What country is Aethlon Medical from?

Aethlon Medical is headquartered in United States

When did Aethlon Medical go public?

Aethlon Medical initial public offering (IPO) was on 04 March 1999

What is Aethlon Medical website?

https://www.aethlonmedical.com

Is Aethlon Medical in the S&P 500?

No, Aethlon Medical is not included in the S&P 500 index

Is Aethlon Medical in the NASDAQ 100?

No, Aethlon Medical is not included in the NASDAQ 100 index

Is Aethlon Medical in the Dow Jones?

No, Aethlon Medical is not included in the Dow Jones index

When was Aethlon Medical the previous earnings report?

No data

When does Aethlon Medical earnings report?

The next expected earnings date for Aethlon Medical is 14 February 2025